-
Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced positive results from a clinical study of its pipeline candidate, the antibody drug conjugate (ADC) 9MW2821, which targets Nectin-4. The data, highlighting the potential of 9MW2821 in treating cervical cancer, is set to be presented…
-
Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth
•
Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder CBridge Capital and executive directors Luo Yongqing and He Ying not to reduce their holdings for at least six months, according to a statement submitted to the Hong Kong Stock Exchange. This pledge reflects their…
-
Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market
•
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide) take the lead in total US prescriptions over its competitor Eli Lilly’s (NYSE: LLY) Zepbound (tirzepatide), according to Reuters. Despite this, Zepbound has seen more new prescriptions filled, indicating a close competition in a market…
-
FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma
•
An advisory committee to the US Food and Drug Administration (FDA) has recommended the use of Abecma (idecabtagene vicleucel), a CAR-T therapy developed by Bristol Myers Squibb (BMS; NYSE: BMY) and 2seventy bio (NASDAQ: TSVT), for the treatment of triple-class exposed (TCE) relapsed or refractory multiple myeloma (r/rMM). This recommendation…
-
Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase I clinical trial for HLX42, an antibody-drug conjugate (ADC) co-developed with Suzhou-based Medilink Therapeutics. The study will initially evaluate HLX42 in patients with advanced or metastatic solid tumors in China. HLX42 is an innovative ADC…
-
AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline
•
AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt Pharma for an upfront payment of $800 million, with an additional potential milestone payment of $250 million. The transaction is anticipated to close by the third quarter of 2024, pending customary regulatory approvals. Amolyt Pharma…
-
KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma
•
Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug HL-085, aimed at treating advanced melanoma with NRAS mutations in patients who have experienced failure with anti-PD-1/PD-L1 therapies. HL-085 is a groundbreaking ATP non-competitive MEK inhibitor that specifically targets NRAS…
-
Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
•
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo Nordisk’s controlling shareholder, Novo Holdings, have participated in a EUR 30 million (USD 32.6 million) Series A financing round for Sweden-based Asgard Therapeutics. Asgard Therapeutics specializes in in in vivo cell reprogramming for cancer immunotherapy,…
